About Nimesh Jaiswal
Nimesh Jaiswal's fervent interest in analyzing and interpreting financial data led him to a career as a financial analyst and journalist. The importance of financial statements in driving a stock’s price is the key approach that he follows while advising investors in his articles.
Nimesh majored in accounting and finance in college and is currently pursuing a CMA (Cost & Management Accountant) program.
Recent Articles By Nimesh Jaiswal
3 Ultra-Popular Stocks to Avoid Now
The major stock market indexes have been hovering near their all-time highs of late despite concerns surrounding the resurgence of COVID-19 cases and rising inflation. Against this backdrop, we think it is wise to avoid famous stocks DoorDash (DASH), Palantir (PLTR), and Aurora Cannabis (ACB). They look overvalued at their current price levels. Read on.
PayPal vs. Visa: Which Stock is a Better Choice?
Despite data privacy concerns by users of digital financial transaction platforms, the market is expected to boom owing to the rapid adoption of advanced technological solutions. So, we think established fintech companies Visa (V) and PayPal (PYPL) should benefit from the industry tailwinds. But which of these two stocks is a better buy now? Read more to find out.
3 ETFs to Protect Your Portfolio from Rising Inflation
Because rising inflation, together with other factors, could keep the stock market under pressure in the near term, we think it could be wise to bet on ETFs that are exposed to industries that are less susceptible to market volatility. To that end, we believe the following ETFs, Energy , Select Sector SPDR Fund (XLE), VanEck Vectors Gold Miners ETF (GDX), and Consumer Staples Select Sector SPDR Fund (XLP), could be solid bets now. So please read on for a more detailed explanation.
Illumina vs. CRISPR: Which Genomics Stock is a Better Choice?
The genomics industry has been the recipient of immense investor attention owing to its crucial role in the genome sequencing of the deadly COVID-19 virus. As the need for gene-based tests is on the rise for next-generation sequencing data for treating several diseases, we think genomics companies Illumina (ILMN) and CRISPR (CRSP) should benefit. But which of these two stocks is a better buy now? Read more to find out.
Forget Robinhood, Buy These 4 Financial Services Stocks Instead
Shares of Robinhood (HOOD) look overvalued at their current price level considering the company’s bleak growth prospects and its stock’s volatility. So, we think it is better to bet on established financial services stocks Discover (DFS), Synchrony (SYF), KeyCorp (KEY), and Raymond James (RJF), which are well-positioned to capitalize on increasing financial transactions and capital market activities. So, let’s examine these names.
2 Bargain Stocks You Can Buy Right Now
As the major stock market indexes hit fresh highs, most quality stocks are currently trading at sky-high valuations, making it difficult to find true value stocks. Intel (INTC) and Bristol-Myers (BMY) have immense growth potential, but their valuations still look reasonable at their current price levels. So, we think it could be wise to scoop up their shares now.
4 Commodity Stocks to Buy on Dips
Even though the rapid spread of the COVID-19 Delta variant has been worrying investors, interest in commodities is soaring. That’s because President Biden’s infrastructure bill makes the prospects bright for several commodities. Consequently, we think it could be wise to bet on quality commodities stocks, Rio Tinto (RIO), Glencore (GLNCY), Fortescue Metals (FSUGY), and Vedanta (VEDL). They are currently trading below their 52-week price highs but have immense growth potential. Let’s look closer
Upstart Holdings vs. 360 Finance: Which FinTech Stock is a Better Choice?
Fintech companies have been in the limelight owing to a significant increase in remote financial transactions amid the COVID-19 pandemic. The trend is expected to continue in the foreseeable future thanks to rapid digitalization. So, both 360 DigiTech (QFIN) and Upstart Holdings (UPST) could witness increasing demand for their solutions. But which of these two stocks is a better buy now? Read more to find out.
3 No-Brainer Biotech Stocks to Invest $2,000 in Right Now
The biotech industry is playing a crucial role in fighting against COVID-19 and is also making considerable progress in finding cures for several other diseases with the help of advanced technologies. With continuing innovation and strong financials, we think biotech concerns Takeda Pharmaceutical (TAK), Exelixis (EXEL), and Vanda Pharmaceuticals (VNDA) are well-positioned to continue benefiting from the industry’s solid growth prospects. So read on for details.